Literature DB >> 18829308

Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds.

Michael Sabio1, Kenneth Jones, Sid Topiol.   

Abstract

The recently published X-ray structures of the beta(2)-adrenergic receptor are the first examples of ligand-mediated GPCR crystal structures. We have previously performed computational studies that examine the potential viability of these structures for use in drug design, exploiting known ligand activities. Our previous study and a newly reported beta(2)/Timolol X-ray complex provide validation of the computational approaches. In the present work, we use the X-ray structures to extract, via in silico high-throughput docking, compounds from proprietary and commercial databases and demonstrate the successful identification of active compounds by radioligand binding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829308     DOI: 10.1016/j.bmcl.2008.09.046

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  28 in total

1.  Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4.

Authors:  Michael M Mysinger; Dahlia R Weiss; Joshua J Ziarek; Stéphanie Gravel; Allison K Doak; Joel Karpiak; Nikolaus Heveker; Brian K Shoichet; Brian F Volkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 2.  New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors.

Authors:  Kenneth A Jacobson; Stefano Costanzi
Journal:  Mol Pharmacol       Date:  2012-06-13       Impact factor: 4.436

3.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.

Authors:  Chris de Graaf; Albert J Kooistra; Henry F Vischer; Vsevolod Katritch; Martien Kuijer; Mitsunori Shiroishi; So Iwata; Tatsuro Shimamura; Raymond C Stevens; Iwan J P de Esch; Rob Leurs
Journal:  J Med Chem       Date:  2011-11-07       Impact factor: 7.446

Review 4.  Recent advances in structure-based virtual screening of G-protein coupled receptors.

Authors:  Subramaniam Ananthan; Wei Zhang; Judith Varady Hobrath
Journal:  AAPS J       Date:  2009-03-17       Impact factor: 4.009

5.  Muscarinic receptors as model targets and antitargets for structure-based ligand discovery.

Authors:  Andrew C Kruse; Dahlia R Weiss; Mario Rossi; Jianxin Hu; Kelly Hu; Katrin Eitel; Peter Gmeiner; Jürgen Wess; Brian K Kobilka; Brian K Shoichet
Journal:  Mol Pharmacol       Date:  2013-07-25       Impact factor: 4.436

Review 6.  Structural insights into adrenergic receptor function and pharmacology.

Authors:  Brian K Kobilka
Journal:  Trends Pharmacol Sci       Date:  2011-03-15       Impact factor: 14.819

Review 7.  Progress in elucidating the structural and dynamic character of G Protein-Coupled Receptor oligomers for use in drug discovery.

Authors:  A Bortolato; J C Mobarec; D Provasi; M Filizola
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Identification of functionally important residues of the silkmoth pheromone biosynthesis-activating neuropeptide receptor, an insect ortholog of the vertebrate neuromedin U receptor.

Authors:  Takeshi Kawai; Yukie Katayama; Linjun Guo; Desheng Liu; Tatsuya Suzuki; Kou Hayakawa; Jae Min Lee; Toshihiro Nagamine; J Joe Hull; Shogo Matsumoto; Hiromichi Nagasawa; Masaru Tanokura; Koji Nagata
Journal:  J Biol Chem       Date:  2014-05-20       Impact factor: 5.157

9.  Structure-based discovery of A2A adenosine receptor ligands.

Authors:  Jens Carlsson; Lena Yoo; Zhan-Guo Gao; John J Irwin; Brian K Shoichet; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

10.  Mapping the druggable allosteric space of G-protein coupled receptors: a fragment-based molecular dynamics approach.

Authors:  Anthony Ivetac; J Andrew McCammon
Journal:  Chem Biol Drug Des       Date:  2010-07-05       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.